Terms: = Prostate cancer AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027 AND Treatment
7 results:
1. Phase 2 clinical trial of torc1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.
George DJ; Halabi S; Healy P; Jonasch D; Anand M; Rasmussen J; Wood SY; Spritzer C; Madden JF; Armstrong AJ
Urol Oncol; 2020 Mar; 38(3):79.e15-79.e22. PubMed ID: 31522863
[TBL] [Abstract] [Full Text] [Related]
2. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.
Koshkin VS; Mir MC; Barata P; Gul A; Gupta R; Stephenson AJ; Kaouk J; Berglund R; Magi-Galluzzi C; Klein EA; Dreicer R; Garcia JA
Invest New Drugs; 2019 Jun; 37(3):559-566. PubMed ID: 31037562
[TBL] [Abstract] [Full Text] [Related]
3. A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.
Graham L; Banda K; Torres A; Carver BS; Chen Y; Pisano K; Shelkey G; Curley T; Scher HI; Lotan TL; Hsieh AC; Rathkopf DE
Invest New Drugs; 2018 Jun; 36(3):458-467. PubMed ID: 29508246
[TBL] [Abstract] [Full Text] [Related]
4. torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
[TBL] [Abstract] [Full Text] [Related]
5. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract] [Full Text] [Related]
6. The torc1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract] [Full Text] [Related]
7. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.
Armstrong AJ; Netto GJ; Rudek MA; Halabi S; Wood DP; Creel PA; Mundy K; Davis SL; Wang T; Albadine R; Schultz L; Partin AW; Jimeno A; Fedor H; Febbo PG; George DJ; Gurganus R; De Marzo AM; Carducci MA
Clin Cancer Res; 2010 Jun; 16(11):3057-66. PubMed ID: 20501622
[TBL] [Abstract] [Full Text] [Related]
